Condition: Lung Cancer · Liver Cancer · Solid Tumor, Adult · Sponsor: Second Affiliated Hospital of Guangzhou Medical University
This trial is designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by intra-tumor (IT) injection of multiple drugs including CTLA4, PD1, and/or PDL1 antibodies combined with drugs-eluting beads loaded with IL2, chemodrug, anti-angiogenesis drug, et. al that will be recommended by an AI-based medical software named IRSW-MIM developed by a cooperating company.
This description comes directly from the study's public registry record.
Zhenfeng Zhang, MD, PhD · +862039195966 · zhangzhf@gzhmu.edu.cn
Bingjia He, MD · +862039195965 · 464677938@qq.com
Always discuss trial participation with your own doctor first.
| Second Affiliated Hospital of Guangzhou Medical University | Guangzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06478108